Phase I
The companies said the collaboration recognizes a “great need for novel treatments in the area of neuropsychiatric medicine development.”
EDIT-101 targets a disease-causing mutation in the CEP290 gene that causes degeneration in ocular photoreceptor cells, which are critical for normal vision.
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.
The Phase I randomized, double-blind, placebo-controlled, single ascending dose study will assess the tolerability and safety of the compound PDC-APB when delivered via intramuscular injection.
Codagenix Inc. announced positive safety and immunogenicity data from a Phase I dose-escalation trial of its single-dose intranasal COVI-VAC vaccine.
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.
Biopharma companies big and small are presenting exciting clinical studies at the European Society for Medical Oncology Congress 2021.
The FDA’s IND approval sets the stage for the very first Phase I/II trial to evaluate EBT-101 as a functional cure for chronic HIV based on the endpoints of safety, tolerability, and efficacy.
It was a very busy week for clinical trial announcements, although there were only three that were COVID-19-related. Here’s a look.
This week, the mRNA leader followed up its announcement of a collaboration with the Institute for Life Changing Medicines (ILCM), with an update on several programs advancing in its pipeline.
PRESS RELEASES